Clinical trials: Liver Malignancy
Liver Carcinoma
CIRSE Registry for SIR-Spheres Therapy
The administration of SIR-Spheres microspheres (yttrium-90 resin microspheres) is a form of selective internal radiation therapy (SIRT) for the treatment of patients with primary and secondary liver tumours.
- Trial name
- CIRT (NCT02305459)
- Testing
- Yttrium-90 loaded SIR-Spheres microspheres, QLQ-C30 with HCC module
- Where
- Austria
- Volunteers
- 1,051 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Neuroendocrine Tumors
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
The purpose of this study is to verify if adding a locoregional treatment of liver metastasis (with trans-arterial embolization-TAE) to medical treatments of proven efficacy can prolong the progression free survival of patients…
- Trial name
- LOTUS (NCT01755182)
- Testing
- approved pharmacologic therapy, TAE
- Where
- 12 sites in Italy
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute, Naples
Hepatocellular Carcinoma, Cholangiocarcinoma
Open Versus Laparoscopic Ablation of Liver Malignancies
The purpose of this study is to compare laparoscopic ablation to open ablation of liver malignancies regarding complication rates and ablation response as well as quality of life following the surgery.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- OPTIMAL (NCT06304766)
- Testing
- Laparoscopic ablation, Open ablation
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatocellular Carcinoma, Esophagogastric Varices
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma
The study is aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with endoscopic therapy for unresectable hepatocellular carcinoma (HCC) complicated with esophagogastric varices (EGV) and seek out…
- Trial name
- NCT05017922
- Testing
- transarterial chemoembolization combined with endoscopic therapy
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Qilu Hospital of Shandong University
Hepatocellular Carcinoma
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment.
- Trial name
- NCT00287222
- Testing
- Bevacizumab, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Arkansas
Hepatocellular Carcinoma, Donafenib
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to…
- Trial name
- NCT05205629
- Testing
- Donafenib combined with TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer, Tumour
Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection
Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to reduce blood loss and blood transfusion requirements in the following patient populations: multisystem trauma, liver transplantation, cardiac surgery and…
- Conditions
- Cancer, Tumour, Surgery
- Trial name
- NCT01651182
- Testing
- No tranexamic acid, Tranexamic Acid
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
HCC - Hepatocellular Carcinoma, Radiotherapy
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Immune checkpoint inhibitors (ICIs) have significantly improved the survival outcomes of HCC patients. However, a considerable proportion of patients eventually experience disease progression due to the development of resistance.
- Trial name
- NCT06870942
- Testing
- Maintenance first-line treatment plus radiation therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
HepatoCellular Carcinoma
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Liver cancer is a common malignant tumor in China, and its incidence rate ranks third and remains high. The treatment of liver cancer has made some progress in recent years, mainly the progress of radical treatment such as…
- Trial name
- NCT04152356
- Testing
- PD-1, Sorafenib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangxi Medical University
Primary Liver Cancer
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.
- Trial name
- NCT03178929
- Testing
- S-Adenosyl Methionine
- Volunteers
- 207 people
- Sponsor
- Beijing Insight Science & Technology Co. Ltd.
Hepatocellular Carcinoma
the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma
evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.
- Trial name
- NCT03777475
- Testing
- transarterial infusion
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatitis C, Chronic
Primary Prevention Hepatocellular Carcinoma by Metformin
Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance.
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Chronic, Cirrhosis
- Trial name
- METFOVIR (NCT02319200)
- Testing
- Metformin
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Non-intervention observation to evaluate the safety and efficacy of immune checkpoint inhibitors alone or combined with molecular targeted drugs / local interventional therapy in patients with advanced liver cancer, and to…
- Trial name
- NCT05609695
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy…
- Trial name
- NCT04327700
- Testing
- TheraBionic, Regorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb